PD-L1 scoring can be tricky. See those positive cells? Well, those are macrophages, not tumor cells, which are negative in this case.
When focal or weak, it can be difficult distinguishing 1%.
Keep this in mind when you read your next report, and consider reaching out to your pathologist to elaborate further on the results.
Interesting study out of Moffitt examining resistance pathways in response to KRAS G12C inhibitor treatment.
Lung Cancer Cells Have Differential Signaling Responses to KRAS Inhibitor Treatment
TAMPA, Fla. - Genetic alterations of the KRAS gene are some of the most common mutations in lung cancer patients, but unfortunately these patients have few effective treatment options. Drugs...
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C Mutant Non-Small Cell Lung Cancer
Source : https://clincancerres.aacrjournals.org/content/early/2021/02/05/1078-0432.CCR-20-4023.abstract
Purpose: KRAS mutations are identified in ~30% of patients with NSCLC. Novel direct inhibitors of KRAS G12C have shown activity in early phase clinical trials. We hypothesized patients with KRAS...
Dual MAPK and HDAC inhibition rewires the apoptotic rheostat to trigger colorectal cancer cell death
Source : https://europepmc.org/article/ppr/ppr283530
The EGFR/RAS/MEK/ERK signalling pathway (ERK/MAPK) is hyper-activated in most colorectal cancers (CRCs). A current limitation of inhibitors of this pathway is that they primarily induce cytostatic effects in CRC cells....
Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals
Source : https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1009368
Author summary The diagnosis of a malignant tumor is preceded by a long process of tumor evolution, characterized by the gradual accumulation of driver mutations, genomic alterations that give cancer...